Clinical trials evaluating SCENESSE® as an adjunct therapy to narrowband UVB (NB-UVB) in generalised vitiligo were announced in 2010. The first of these trials was completed in late 2012, with results available on our website. We also published an in-depth Q&A on these trial results on our blog. A further, Phase II, study commenced in Singapore in 2014.
At present there are no timelines available for the drug's commercial availability for vitiligo in any country; we must first conduct clinical trials to determine if the drug is safe and effective. Further trials are planned, but we are yet to announce the exact timing or location of these studies. This process takes time and we appreciate your patience while the company progresses its program. If you are interested in participating in clinical research, it is best to speak with your treating dermatologist first - they are best placed to evaluate your suitability for any study.